教育经历 1983.09-1987.08 四川大学/化学/学士 1987.09-1990.08 四川大学/化学/硕士 1993.09-1996.08 中国科学院上海药物研究所/有机化学/博士 工作经历 1990.09-1993.08 西安近代化学研究所/工程师 1996.09-1998.08 中国科学院上海药物研究所/博士后 1998.09-至今 中国科学院上海药物研究所/课题组长 2021.11-至今 中科中山药物创新研究院/课题组长

原创性抗感染药物、抗凝血药物、抗肿瘤药物研究与开发 主要从事基于知识的原创性抗感染药物、抗凝血药物、抗肿瘤药物研究与开发。代表性成果是2009年成功研制出我国第一个具有自主知识产权的氟喹诺酮新药—盐酸安妥沙星，填补了我国该领域40余年的空白。和现有同类药物相比，本品在安全性、疗效、药代动力学均具有明显的优势。

Liu Q, Kistemaker HAV, Bhogaraju S, Dikic I, Overkleeft HS, van der Marel GA, Ovaa H, van der Heden van Noort GJ, Filippov DV. A General Approach Towards Triazole-Linked Adenosine Diphosphate Ribosylated Peptides and Proteins. Angew Chem Int Ed Engl 2018. 57(6), 1659-1662. (IF=15.336) Liu Q, Knobloch G, Voorneveld J, Meeuwenoord NJ, Overkleeft HS, van der Marel GA, Andreas G. Ladurner AG, Filippov DV. Chemical Synthesis of Linear ADP-ribose Oligomers up to Pentamer and their Binding to the Oncogenic Helicase ALC1. Chem. Sci. 2021 12(37), 12468-12475. (IF=9.825) Kliza KW#*, Liu Q#, Roosenboom LWM, Jansen PWTC, Filippov DV*, Vermeulen M*. Reading ADP-ribosylation signaling using chemical biology and interaction proteomics. Mol. Cell 2021 81(21), 4552-4567. (IF=17.970，#同等贡献，*通讯作者) Rack JGM#, Liu Q#, Zorzini V, Voorneveld J, Ariza A, Honarmand Ebrahimi K, Reber JM, Krassnig SC, Ahel D, van der Marel GA, Mangerich A, McCullagh JSO, Filippov DV*, Ahel I*. Mechanistic insights into the three steps of poly(ADP-ribosylation) reversal. Nat Commun 2021. 12(1), 4581 (IF=14.919, #同等贡献) Liu Q, Kistemaker HAV, Overkleeft HS, van der Marel GA, Filippov DV. Synthesis of ribosyl-ribosyl-adenosine-5 ',5 '',5'''(triphosphate)-the naturally occurring branched fragment of poly(ADP ribose). Chem. Commun. 2017. 53(74), 10255-10258. (IF=6.222, 封面文章) Liu Q, Florea BI, Filippov DV. ADP-Ribosylation Goes Normal: Serine as the Major Site of the Modification. Cell Chem Biol 2017. 24(4), 431-432. (IF=7.739, 综述) Liu Q#, Qiang X#, Li Y, Sang Z, Li Y, Tan Z, Deng Y. Design, synthesis and evaluation of chromone-2-carboxamido-alkylbenzylamines as multifunctional agents for the treatment of Alzheimer’s disease. Bioorg. Med. Chem. 2015. 23(5), 911-23 (IF=3.641, #同等贡献) Liu Q, van der Marel GA, Filippov DV. Chemical ADP-ribosylation: mono-ADPr-peptides and oligo-ADP-ribose. Org Biomol Chem 2019. 17(22), 5460-5474. (IF=3.412, 综述) Voorneveld J, Rack JGM, van Gijlswijk L, Meeuwenoord NJ, Liu Q, Overkleeft HS, van der Marel GA, Ahel I, Filippov DV. Molecular Tools for the Study of ADP-Ribosylation: A Unified and Versatile Method to Synthesise Native Mono-ADP-Ribosylated Peptides. Chem. Eur. J. 2021. 27(41), 10621-10627. (IF=5.236) Qiang XM, Sang ZP, Yuan W, Li Y, Liu Q, Bai P, Shi YK, Tan ZH, Deng Y. Design, synthesis and evaluation of genistein-O-alkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 2014. 76, 314-31. (IF=6.514) Sang Z., Qiang X., Li Y., Yuan W., Liu Q., Shi Y., Ang W., Luo Y., Tan Z., Deng Y. Design, synthesis and evaluation of scutellarein-O-alkylamines as multifunctional agents for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 2015. 94, 348-66. (IF=6.514) Sang Z., Li Y., Qiang X., Xiao G., Liu Q., Tan Z., Deng Y. Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease. Bioorg. Med. Chem. 2015. 23(4), 668-80. (IF=3.412)